NCT03710655View on ClinicalTrials.gov

Evaluate Safety and Efficacy of Apitox Add-on Therapy for Improving Disability and Quality of Life in MS Patients

PHASE3UnknownINTERVENTIONAL
Enrollment

468

Participants

Timeline

Start Date

April 30, 2019

Primary Completion Date

August 31, 2019

Study Completion Date

November 30, 2019

Conditions
Multiple Sclerosis
Interventions
DRUG

Apitox - pure honeybee toxin

Intradermal injection of 0.01 microliters

DRUG

Placebo

Intradermal injection of 0.01 microliters

Sponsors

Lead Sponsor

Apimeds, Inc.
All Listed Sponsors
lead

Apimeds, Inc.

INDUSTRY